| Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 397 (10285), 1637, 2021 | 2867* | 2021 |
| Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind … HGM Heijerman, EF McKone, DG Downey, E Van Braeckel, SM Rowe, ... The Lancet 394 (10212), 1940-1948, 2019 | 1243 | 2019 |
| RECOVERY Collaborative Group Dexamethasone in hospitalized patients with Covid-19 P Horby, WS Lim, JR Emberson, M Mafham, JL Bell, L Linsell, N Staplin, ... N Engl J Med 384 (8), 693-704, 2021 | 638* | 2021 |
| Neutrophils in cystic fibrosis DG Downey, SC Bell, JS Elborn Thorax 64 (1), 81-88, 2009 | 275 | 2009 |
| Safety and Efficacy of Recombinant Alpha1‐Antitrypsin Therapy in Cystic Fibrosis SL Martin, D Downey, D Bilton, MT Keogan, J Edgar, JS Elborn Pediatric pulmonology 41 (2), 177-183, 2006 | 119 | 2006 |
| Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week … S Sutharsan, EF McKone, DG Downey, J Duckers, G MacGregor, E Tullis, ... The Lancet Respiratory Medicine 10 (3), 267-277, 2022 | 114 | 2022 |
| Future therapies for cystic fibrosis L Allen, L Allen, SB Carr, G Davies, D Downey, M Egan, JT Forton, R Gray, ... Nature communications 14 (1), 693, 2023 | 92 | 2023 |
| Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open … O Abani, A Abbas, F Abbas, J Abbas, K Abbas, M Abbas, S Abbasi, ... The Lancet 401 (10387), 1499-1507, 2023 | 79 | 2023 |
| The relationship of clinical and inflammatory markers to outcome in stable patients with cystic fibrosis DG Downey, SL Martin, M Dempster, JE Moore, MT Keogan, B Starcher, ... Pediatric pulmonology 42 (3), 216-220, 2007 | 77 | 2007 |
| The effect of treatment of cystic fibrosis pulmonary exacerbations on airways and systemic inflammation DG Downey, S Brockbank, SL Martin, M Ennis, JS Elborn Pediatric pulmonology 42 (8), 729-735, 2007 | 75 | 2007 |
| Failure to conceive in women with CF is associated with pancreatic insufficiency and advancing age M Shteinberg, AB Lulu, DG Downey, Z Blumenfeld, C Rousset-Jablonski, ... Journal of Cystic Fibrosis 18 (4), 525-529, 2019 | 67 | 2019 |
| CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis JL Taylor-Cousar, PD Robinson, M Shteinberg, DG Downey The Lancet 402 (10408), 1171-1184, 2023 | 60 | 2023 |
| Airway inflammation and host responses in the era of CFTR modulators K Keown, R Brown, DF Doherty, C Houston, MC McKelvey, S Creane, ... International journal of molecular sciences 21 (17), 6379, 2020 | 55 | 2020 |
| Coinfection with Pseudomonas aeruginosa and Aspergillus fumigatus in cystic fibrosis K Keown, A Reid, JE Moore, CC Taggart, DG Downey European Respiratory Review 29 (158), 2020 | 52 | 2020 |
| Current pregnancy outcomes in women with cystic fibrosis C Burden, R Ion, Y Chung, A Henry, DG Downey, J Trinder European Journal of Obstetrics & Gynecology and Reproductive Biology 164 (2 …, 2012 | 49 | 2012 |
| VX17-445-103 Trial Group Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del … HGM Heijerman, EF McKone, DG Downey, E Van Braeckel, SM Rowe, ... Lancet 394 (10212), 1940-1948, 2019 | 48 | 2019 |
| Nitric oxide, iNOS, and inflammation in cystic fibrosis D Downey, JS Elborn The Journal of Pathology: A Journal of the Pathological Society of Great …, 2000 | 47 | 2000 |
| Effect of cystic fibrosis exacerbations on neutrophil function S Brockbank, D Downey, JS Elborn, M Ennis International immunopharmacology 5 (3), 601-608, 2005 | 46 | 2005 |
| The effect of CFTR modulators on airway infection in cystic fibrosis C Harvey, S Weldon, S Elborn, DG Downey, C Taggart International Journal of Molecular Sciences 23 (7), 3513, 2022 | 44 | 2022 |
| Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND … PA Flume, RF Biner, DG Downey, C Brown, M Jain, R Fischer, ... The lancet respiratory medicine 9 (7), 733-746, 2021 | 44 | 2021 |